Intercept Pharmaceuticals, Inc. Logo
 
Press Releases
Date Title and Summary View
Sep 4, 2012 New York, NY, September 4, 2012 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission...
Aug 9, 2012 NEW YORK, August 9, 2012 -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced the completion of a $30 million Series C preferred stock financing led by OrbiMed Advisors LLC, a leading gl...
Sep 8, 2011
Mar 31, 2011
Mar 30, 2011
Mar 29, 2011
Apr 13, 2010
Jan 25, 2010
Oct 27, 2009
Oct 1, 2009
Page: FirstPrevious ...
15
NextLast
= add release to Briefcase